Option Care Health (NASDAQ:OPCH) Raised to Strong-Buy at Stephens

Option Care Health (NASDAQ:OPCH) was upgraded by analysts at Stephens to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

OPCH has been the topic of a number of other research reports. Deutsche Bank Aktiengesellschaft upped their target price on shares of Option Care Health from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday. Bank of America raised their price objective on shares of Option Care Health from $32.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday. TD Cowen reduced their target price on Option Care Health from $30.00 to $27.00 and set a “hold” rating on the stock in a report on Monday, November 3rd. Citigroup reiterated an “outperform” rating on shares of Option Care Health in a report on Friday, October 31st. Finally, Citizens Jmp dropped their price objective on shares of Option Care Health from $38.00 to $36.00 and set a “market outperform” rating on the stock in a report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $36.27.

Option Care Health Stock Performance

OPCH stock traded up $0.34 during trading on Thursday, reaching $33.24. 1,867,592 shares of the stock were exchanged, compared to its average volume of 1,839,138. Option Care Health has a twelve month low of $22.29 and a twelve month high of $35.53. The company has a market capitalization of $5.28 billion, a P/E ratio of 26.38, a price-to-earnings-growth ratio of 2.22 and a beta of 0.80. The stock has a 50 day simple moving average of $28.74 and a 200-day simple moving average of $29.36. The company has a current ratio of 1.56, a quick ratio of 1.05 and a debt-to-equity ratio of 0.85.

Insider Transactions at Option Care Health

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. purchased 38,000 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were purchased at an average cost of $25.98 per share, with a total value of $987,240.00. Following the transaction, the director directly owned 413,390 shares of the company’s stock, valued at $10,739,872.20. This represents a 10.12% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.64% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Durable Capital Partners LP lifted its stake in Option Care Health by 134.2% in the second quarter. Durable Capital Partners LP now owns 8,237,577 shares of the company’s stock valued at $267,557,000 after acquiring an additional 4,720,988 shares during the last quarter. Fuller & Thaler Asset Management Inc. lifted its stake in Option Care Health by 30.8% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 4,204,481 shares of the company’s stock valued at $146,947,000 after purchasing an additional 989,048 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Option Care Health by 17.3% during the third quarter. Arrowstreet Capital Limited Partnership now owns 4,001,307 shares of the company’s stock worth $111,076,000 after purchasing an additional 590,913 shares during the period. Dimensional Fund Advisors LP increased its position in Option Care Health by 6.6% during the third quarter. Dimensional Fund Advisors LP now owns 3,796,396 shares of the company’s stock worth $105,384,000 after buying an additional 235,413 shares during the last quarter. Finally, Norges Bank bought a new stake in Option Care Health in the second quarter valued at approximately $69,932,000. 98.05% of the stock is owned by institutional investors and hedge funds.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.